TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26156151

Group type: EXPERIMENTAL
Intervention: IVUS-guided intervention
Number of subjects: 402

Group type: COMPARATOR
Intervention: Angiography-guided intervention
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent
Number of subjects: 402

Group type: COMPARATOR
Intervention: Nobori biolimus-eluting stent
Number of subjects: 402
Study: 24373253

Group type: COMPARATOR
Intervention: Cable TV intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive programming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced social support
Number of subjects: 0
Study: 21450598

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 266

Group type: COMPARATOR
Intervention: Late invasive strategy
Number of subjects: 266
Study: 20037224

Group type: EXPERIMENTAL
Intervention: Errorless learning (cues provided without errors)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trial‐and‐error learning (cues provided only after an error)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Errorless learning in mild-to-moderate dementia group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trial‐and‐error learning in mild-to-moderate dementia group
Number of subjects: 60
Study: 17768180

Group type: EXPERIMENTAL
Intervention: 10 billion heat-killed L. acidophilus LB plus 160 mg of spent culture medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oral rehydration solution
Number of subjects: 0
Study: 15485934

Group type: EXPERIMENTAL
Intervention: Specialised care group (assertive outreach with evidence based biopsychosocial interventions)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 144
Study: 11837149

Group type: EXPERIMENTAL
Intervention: Propofol at 16 micrograms/kg per minute
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol at 32 micrograms/kg per minute
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (10% intralipids at 16 micrograms/kg per minute and 20% intralipids at 32 micrograms/kg per minute)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol groups (both doses)
Number of subjects: 48
Study: 9755260

Group type: COMPARATOR
Intervention: No cooling (control group; rectal temperature = 37.0 +/- 0.2 degreesC, n = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Minimal systemic cooling (rectal temperature = 36.3 +/- 0.2 degreesC, n = 6)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mild systemic cooling (rectal temperature = 35.7 +/- 0.2 degreesC, n = 6)
Number of subjects: 22
Study: 7820891

Group type: EXPERIMENTAL
Intervention: Calcium sodium alginate (Kaltostat)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Glove finger packs
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Paraffin trouser packs
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nostrils packed for 48 hours
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nostrils packed for 24 hours
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Paraffin gauze packs at 3 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Other packing materials at 3 weeks
Number of subjects: 92
Study: 3134397

Group type: EXPERIMENTAL
Intervention: Long protocol (decapeptyl for 30 days with pure FSH stimulation)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Short protocol (Buserelin for 15 days with pure FSH stimulation)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Long protocol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 27
Study: 30615009

Group type: EXPERIMENTAL
Intervention: Eccentric overload (EOL) exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition (10-minute cycling at 1 W·kg‐1)
Number of subjects: 18
Study: 31095995

Group type: EXPERIMENTAL
Intervention: KET/DEX (0.7 μg/kg/h infusion of dexmedetomidine)
Number of subjects: 39

Group type: COMPARATOR
Intervention: KET/FENT (three 25 μg fentanyl injections over 1.5 h)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ketamine only administration
Number of subjects: 39
Study: 29438092

Group type: EXPERIMENTAL
Intervention: Parsatuzumab (600 mg) in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Number of subjects: 104
Study: 27374839

Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Improvement in renal function (IRF)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Linear increase in creatinine
Number of subjects: 301
Study: 23417572

Group type: EXPERIMENTAL
Intervention: F/Sn/chitosan toothpaste (1,400 ppm F(-), 3,500 ppm Sn(2+), 0.5% chitosan)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GelKam (3,000 ppm Sn(2+), 1,000 ppm F(-))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: F/Sn toothpaste (1,400 ppm F(-), 3,500 ppm Sn(2+))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo toothpaste (negative control)
Number of subjects: 10
Study: 22410113

Group type: EXPERIMENTAL
Intervention: Core-ceramic/veneer (Empress2/Eris or e.max Press core/e.max Ceram glaze)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Enamel antagonists
Number of subjects: 31

Group type: COMPARATOR
Intervention: Enamel contralateral-antagonist
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All wear sites
Number of subjects: 31
Study: 20457512

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 46
Study: 17628889

Group type: EXPERIMENTAL
Intervention: Functional treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryotherapy, electrotherapy, ultrasound
Number of subjects: 0
Study: 16305584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol (1 dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 microg salbutamol (2 doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SLOW inhalation (20 l min(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FAST inhalation (60 l min(‐1))
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LATE inhalation (slow inhalation after 5 s)
Number of subjects: 12
Study: 12079631

Group type: EXPERIMENTAL
Intervention: 1.45 microm diode laser with cryogen spray cooling, average power 12 W, treated on three separate occasions 3 weeks apart.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cryogen spray cooling alone, treated on the contralateral sides as control.
Number of subjects: 9
Study: 10442547

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg twice daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg once daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg once daily for a further 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7778170

Group type: EXPERIMENTAL
Intervention: ATG (ATGAM) administered in variable doses to maintain the absolute number of peripheral CD3 T cells at 50-100/microliters (Group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: ATG given at a fixed dose of 15 mg/kg/day (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups received azathioprine and prednisone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group 1 (variable dosing) vs Group 2 (fixed dosing)
Number of subjects: 45
Study: 2088233

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg for 14 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 104724

Group type: EXPERIMENTAL
Intervention: Sodium 2-mercapto-ethane sulphonate aerosol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline aerosol (placebo)
Number of subjects: 11
Study: 30720382

Group type: EXPERIMENTAL
Intervention: eBook training
Number of subjects: 148

Group type: COMPARATOR
Intervention: Face-to-face training
Number of subjects: 148
Study: 30940694

Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (3 mg) with dodecyl maltoside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular nalmefene (1.5 mg)
Number of subjects: 0
Study: 29894921

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) - 60-minute session
Number of subjects: 130

Group type: COMPARATOR
Intervention: Reassurance - 15-minute session
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 26829933

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (1 x 20 Gy)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Conventional radiotherapy (1 x 8 Gy)
Number of subjects: 386
Study: 24144736

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (no statin therapy)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Age >70 years
Number of subjects: 351

Group type: COMPARATOR
Intervention: History of cardiac disease
Number of subjects: 351

Group type: COMPARATOR
Intervention: Moderate/severe tobacco use
Number of subjects: 351
Study: 23192500

Group type: EXPERIMENTAL
Intervention: 3.8% milk
Number of subjects: 90

Group type: COMPARATOR
Intervention: water
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.1% gastrografin
Number of subjects: 90
Study: 21036355

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Omega-3 ethyl esters 90 2g
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Atorvastatin in low cholesterol synthesisers with high absorption
Number of subjects: 658
Study: 17337382

Group type: EXPERIMENTAL
Intervention: Combination treatment using HDAC inhibitors and PPARγ agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPARγ agonists (thiazolidinediones)
Number of subjects: 0
Study: 16351564

Group type: EXPERIMENTAL
Intervention: 3 months at altitude (4,500 m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 13 months at altitude (4,500 m)
Number of subjects: 0
Study: 17251695

Group type: EXPERIMENTAL
Intervention: Exercise intervention group
Number of subjects: 171

Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 171
Study: 10937517

Group type: EXPERIMENTAL
Intervention: Thalidomide (150 mg orally at bedtime)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8990407

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention within the first 3 days post-MI
Number of subjects: 0
Study: 1353350

Group type: EXPERIMENTAL
Intervention: Walk/stair climb (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Walk/stand activity protocol (control group)
Number of subjects: 40
Study: 6373264

Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d.
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d. in patients <65 years
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo in patients <65 years
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d. in patients <65 years continuing medication
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo in patients <65 years continuing medication
Number of subjects: 1741
Study: 31179743

Group type: EXPERIMENTAL
Intervention: Radiotherapy in PD-L1-low-radioresistant (RR) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment in PD-L1-low-RR group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGF19 and PLA2G5 expression in PD-L1-low-RR group
Number of subjects: 0
Study: 30515654

Group type: EXPERIMENTAL
Intervention: Sperm collected at the middle of spawning period
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sperm collected at the beginning of spawning period
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sperm volume measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sperm density measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sperm velocity measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Percentage of motile sperm
Number of subjects: 100
Study: 27557813

Group type: EXPERIMENTAL
Intervention: Social environmental intervention (group motivational interviewing delivered by team leaders)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Physical environmental intervention (environmental modifications)
Number of subjects: 329
Study: 24989892

Group type: EXPERIMENTAL
Intervention: Trastuzumab and chemotherapy (arms B and C)
Number of subjects: 1325

Group type: EXPERIMENTAL
Intervention: Trastuzumab (arm C)
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Chemotherapy only (arm A)
Number of subjects: 1325
Study: 22897892

Group type: EXPERIMENTAL
Intervention: Diaphragm Pacing (DP) in addition to Non Invasive Ventilation (NIV)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non Invasive Ventilation (NIV)
Number of subjects: 108
Study: 20427981

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Optimal intensity of RRT
Number of subjects: 1000
Study: 18245417

Group type: EXPERIMENTAL
Intervention: Trained providers
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control providers
Number of subjects: 418
Study: 16408409

Group type: EXPERIMENTAL
Intervention: Driving simulator
Number of subjects: 12

Group type: COMPARATOR
Intervention: Real driving
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sleep restricted condition (2 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled habitual sleep (8 hours)
Number of subjects: 12
Study: 12635059

Group type: EXPERIMENTAL
Intervention: High-frequency, low-volume ventilation with 100% oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-frequency, low-volume ventilation with 21% oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) with 100% oxygen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) with 21% oxygen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Disconnected from the ventilator during the bypass period
Number of subjects: 75
Study: 10784292

Group type: EXPERIMENTAL
Intervention: Stress management training led by external clinical psychologists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress management training led by paraprofessionals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 0
Study: 8683682

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) instillation (120 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Mitomycin C instillation (40 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 261

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 261
Study: 1993497

Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 31979294

Group type: EXPERIMENTAL
Intervention: Prediction model with glycemic index (GI) and glycemic load (GL) included
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prediction model without glycemic index (GI) and glycemic load (GL)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prediction model with GI/GL for new patients
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Prediction model without GI/GL for new patients
Number of subjects: 124
Study: 30728377

Group type: EXPERIMENTAL
Intervention: Total anti-HAV detected using Chemiluminescent Enzyme Immunoassay
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Individuals aged 20-59 years
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Individuals aged 70s
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: HAV vaccine
Number of subjects: 1200
Study: 27040557

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) targeting social skills and anxiety
Number of subjects: 25
Study: 25627290

Group type: EXPERIMENTAL
Intervention: LSCS group
Number of subjects: 20

Group type: COMPARATOR
Intervention: LDH group
Number of subjects: 20
Study: 23624296

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21315879

Group type: EXPERIMENTAL
Intervention: One-session computer-based exposure (CBE) treatment; 27-minute session with nine fear-eliciting spider pictures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group exposed to nine neutral pictures
Number of subjects: 0
Study: 19608566

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin during IVF and first trimester of pregnancy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo during IVF and first trimester of pregnancy
Number of subjects: 54
Study: 16930908

Group type: EXPERIMENTAL
Intervention: Semi‐automated liquid handling systems with liquid/liquid extraction (LLE) and gradient liquid chromatography tandem mass spectrometry (LC‐MS/MS) for DEX, DET, and GG.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Semi‐automated LLE with LC‐MS/MS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Formulation optimization
Number of subjects: 6
Study: 14986194

Group type: EXPERIMENTAL
Intervention: MetaMax II at 100 W
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MetaMax II at 200 W
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MetaMax II at 250 W
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: MetaMax II at 325 W
Number of subjects: 29
Study: 11549629

Group type: EXPERIMENTAL
Intervention: Transdermal dihydrotestosterone gel (70 mg daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 37
Study: 9489974

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2877

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2877
Study: 7785133

Group type: EXPERIMENTAL
Intervention: Antioxidant treatment (10% dibunol liniment and 5% ascorbic acid) injected 2 times a day, combined with 500,000 U of ampicillin for purulent sinusitis; injected once a day without antibiotic for catarrhal sinusitis.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment (4 ml dioxidine in a single dose for catarrhal sinusitis; 500,000 U ampicillin plus hydrocortisone emulsion 2 times a day for purulent sinusitis).
Number of subjects: 0
Study: 3136831

Group type: EXPERIMENTAL
Intervention: 100 mg recombinant tissue plasminogen activator
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 mg recombinant tissue plasminogen activator
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 mg recombinant tissue plasminogen activator
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All doses of recombinant tissue plasminogen activator
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Successful reperfusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50 mg and 100 mg doses
Number of subjects: 50
Study: 31190781

Group type: EXPERIMENTAL
Intervention: CID- patients (no clinically important deterioration)
Number of subjects: 3769
Study: 28872526

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene liners (E1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Highly cross-linked liners without vitamin E (ArComXL)
Number of subjects: 63
Study: 25587004

Group type: EXPERIMENTAL
Intervention: Jollab
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 24035110

Group type: EXPERIMENTAL
Intervention: Topical doxycycline hyclate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20953874

Group type: EXPERIMENTAL
Intervention: Anterolateral (AL) approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transgluteal (TG) approach
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (AL and TG)
Number of subjects: 40
Study: 19617207

Group type: EXPERIMENTAL
Intervention: Low-dose hCG (200 IU/l daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard treatment with rFSH (Puregon) plus a GnRH‐antagonist
Number of subjects: 70
Study: 17105694

Group type: EXPERIMENTAL
Intervention: Wet cupping (active group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study: 15257305

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11397890

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 9438235

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Medium fat diet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Overall controlled diets
Number of subjects: 29
Study: 8483174

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: 1% diphenhydramine
Number of subjects: 99
Study: 2446078

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30654120

Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACLR)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: First 2 years post-ACL injury
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Last 3 years post-ACL injury
Number of subjects: 121

Group type: COMPARATOR
Intervention: Reference cohort from Osteoarthritis Initiative (OAI)
Number of subjects: 121
Study: 28560774

Group type: EXPERIMENTAL
Intervention: Verapamil (Pgp inhibitor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24